Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes. Part II
暂无分享,去创建一个
G. Lescoat | J. Leger | C. Jarry | F. Gaboriau | P. Sonnet | A. Dassonville-Klimpt | L. Latxague | O. Chassande | J. Guillon | P. Rougé | V. Pires | S. Fardeau | Pascal Rouge
[1] Xiaole Kong,et al. Design of iron chelators with therapeutic application. , 2012, Dalton transactions.
[2] G. Lescoat,et al. Antiproliferative effect on HepaRG cell cultures of new calix[4]arenes , 2010, Journal of enzyme inhibition and medicinal chemistry.
[3] S. Subramanian,et al. On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. , 2008, Bioorganic & medicinal chemistry letters.
[4] L. Mutihac. Functionalized calix[n]arenes as membrane transporters for biological compounds. A minireview. , 2008, Current drug discovery technologies.
[5] W. Wilson,et al. Synthesis and antiprotozoal activity of novel bis-benzamidino imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines. , 2008, Bioorganic & medicinal chemistry.
[6] P. Jose,et al. Lower-Rim Substituted Calixarenes and Their Applications , 2007, Bioinorganic chemistry and applications.
[7] R. Bergeron,et al. The design, synthesis, and evaluation of organ-specific iron chelators. , 2006, Journal of medicinal chemistry.
[8] D. Richardson,et al. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. , 2006, Journal of medicinal chemistry.
[9] C. Raston,et al. Supersized bilayers based on an O-alkyl substituted calix[4]arene , 2006 .
[10] W. Wilson,et al. Synthesis, DNA affinity, and antiprotozoal activity of linear dications: Terphenyl diamidines and analogues. , 2006, Journal of medicinal chemistry.
[11] K. Rauch,et al. Access to Variously Substituted 5,6,7,8‐Tetrahydro‐3H‐quinazolin‐4‐ones via Diels–Alder Adducts of Phenyl Vinyl Sulfone to Cyclobutene‐Annelated Pyrimidinones , 2006 .
[12] S. Perrotta,et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. , 2006, Blood.
[13] G. Lescoat,et al. Modulation of cell proliferation in rat liver cell cultures by new calix[4]arenes , 2006, Journal of enzyme inhibition and medicinal chemistry.
[14] Nolwenn Le Meur,et al. Hepatocyte iron loading capacity is associated with differentiation and repression of motility in the HepaRG cell line. , 2006, Genomics.
[15] D. Richardson,et al. The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer , 2005, Pharmacological Reviews.
[16] K. Fischer,et al. Self-assembly of programmed building blocks into structurally uniform dendrimers. , 2005, Journal of the American Chemical Society.
[17] E. De Clercq,et al. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. , 2005, Journal of medicinal chemistry.
[18] J. Leger,et al. First Synthesis of 1,3-Alternate 25,27-Dialkyloxy-5,17-diarylcalix[4]arenes-crown-6 as New Cesium Selective Extractants by Suzuki Cross-coupling Reaction , 2004 .
[19] D. Richardson,et al. Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity , 2003, American journal of hematology.
[20] B. Hasinoff. The intracellular iron sensor calcein is catalytically oxidatively degraded by iron(II) in a hydrogen peroxide-dependent reaction. , 2003, Journal of inorganic biochemistry.
[21] Christian Trepo,et al. Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[22] D. Richardson,et al. The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.
[23] D. Richardson,et al. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. , 2002, Blood.
[24] J. Leger,et al. Synthesis and Cesium Binding Affinity of New 25,27-Bis(alkyloxy)calix[4]arene-crown-6 Conformers in Relation to the Alkyl Pendent Moiety , 2002 .
[25] J. Porter,et al. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. , 2002, Best practice & research. Clinical haematology.
[26] D. Richardson. Iron chelators as therapeutic agents for the treatment of cancer. , 2002, Critical reviews in oncology/hematology.
[27] R. Hider,et al. Design of clinically useful iron(III)‐selective chelators , 2002, Medicinal research reviews.
[28] D. Richardson,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. , 1995, Blood.
[29] M. Rouan,et al. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. , 2001, Journal of chromatography. B, Biomedical sciences and applications.
[30] J. Leger,et al. Synthesis of Cone, Partial-Cone, and 1,3-Alternate 25,27-Bis[1-(2-ethyl)hexyl]- and 25,27-Bis[1-(2-tert-butoxy)ethyl]calix[4]arene-crown-6 Conformers as Potential Selective Cesium Extractants. , 2001 .
[31] F. Sansone,et al. Calixarenes in Bioogranic and Biomimetic Chemistry , 2001 .
[32] Guillon,et al. Synthesis of cone, partial-cone, and 1,3-alternate 25, 27-Bis , 2000, The Journal of organic chemistry.
[33] G. Lescoat,et al. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. , 2000, Carcinogenesis.
[34] A. Sartorelli,et al. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. , 2000, Biochemical pharmacology.
[35] N. Andrews,et al. Disorders of iron metabolism. , 1999, The New England journal of medicine.
[36] M. Fontecave,et al. Calcein as a Fluorescent Probe for Ferric Iron , 1999, The Journal of Biological Chemistry.
[37] S. E. Matthews,et al. Calix[4]arenes with CMPO functions at the narrow rim. Synthesis and extraction properties , 1999 .
[38] G. Lescoat,et al. Deferoxamine arrests in vitro the proliferation of porcine hepatocyte in G1 phase of the cell cycle. , 2008, Liver.
[39] D. Naidoo,et al. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. , 1998, Cancer research.
[40] D. Richardson. Potential of iron chelators as effective antiproliferative agents. , 1997, Canadian journal of physiology and pharmacology.
[41] D. Richardson,et al. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. , 1997, Blood.
[42] A. Shanzer,et al. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. , 1996, Blood.
[43] U. Ramenghi,et al. Effect of different exposures to desferrioxamine on neuroblastoma cell lines. , 1995, Pediatric hematology and oncology.
[44] J. Olsen,et al. Cancer risk following primary hemochromatosis: A population‐based cohort study in Denmark , 1995, International journal of cancer.
[45] G. Koren,et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. , 1994, Blood.
[46] P. Brissot,et al. Preneoplastic significance of hepatic iron–free foci in genetic hemochromatosis: A study of 185 patients , 1993, Hepatology.
[47] J Lucas,et al. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. , 1993, Cancer research.
[48] A. Hoffbrand,et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. , 1992, Blood.
[49] G. Koren,et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. , 1992, Blood.
[50] A. Casnati,et al. A general synthesis of calix[4]arene monoalkyl ethers , 1991 .
[51] K. Nouri-Aria,et al. Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. , 1990, Immunology.
[52] M. Stahlhut,et al. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. , 1988, Cancer research.
[53] C. Gutsche,et al. Calixarenes. Part 12. The Synthesis of Functionalized Calixarenes. , 1986 .
[54] E. Romano,et al. The effect of desferrioxamine on the proliferative response of rat lymphocytes stimulated with various mitogens in vitro. , 1984, Immunopharmacology.
[55] D Rodbard,et al. Automated computer analysis for enzyme-multiplied immunological techniques. , 1977, Clinical chemistry.
[56] S. S. Berg,et al. 138. The search for chemotherapeutic amidines. Part X. Substituted 4 : 4′-diamidino-αω-diphenoxyalkanes and -diphenyl ethers , 1949 .
[57] E. G. Wakefield,et al. ABSORPTION AND EXCRETION OF IRON , 1945 .